Opioid Withdrawal Syndrome Pipeline Analysis, 2025 By Delveinsight Chiesi Farmaceutici S.P.A., Bioxcel Therapeutics, Aphios Pharmaceutical

(MENAFN- GetNews)


"Opioid Withdrawal Syndrome Pipeline Analysis"DelveInsight's,“Obstructive Sleep Apnea (OSA) Pipeline Insight, 2025” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Obstructive Sleep Apnea (OSA) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Obstructive Sleep Apnea therapeutics assessment by product type, stage, Obstructive Sleep Apnea route of administration, and Obstructive Sleep Apnea molecule type.

DelveInsight reports that the Opioid Withdrawal Syndrome pipeline includes over 4 key companies actively developing more than 4 therapeutic candidates.

Opioid Withdrawal Syndrome Overview:

Opioid Withdrawal Syndrome is a potentially serious condition that arises from dependence on opioids, a class of drugs often prescribed for severe pain. The syndrome occurs when opioid use is abruptly reduced or discontinued after prolonged and heavy use, triggering a variety of withdrawal symptoms. Common symptoms include anxiety, chills or goosebumps, restlessness, insomnia, frequent yawning, runny nose, watery eyes, fever, nausea, vomiting, and diarrhea, among others.

The locus coeruleus, located at the base of the brain, plays a central role in triggering these withdrawal symptoms. Current treatment approaches for Opioid Withdrawal Syndrome include gradual tapering of full opioid agonists such as methadone, short-term use of partial mu-opioid agonists like buprenorphine, and detoxification protocols using opioid antagonists such as naltrexone and naloxone.

Download our report @

"Opioid Withdrawal Syndrome Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Opioid Withdrawal Syndrome Therapeutics Market.

Key Takeaways from the Opioid Withdrawal Syndrome Pipeline Report

• DelveInsight's report on the Opioid Withdrawal Syndrome (OWS) pipeline highlights a focused space, with over 4 companies actively developing more than 4 therapeutic candidates.

• In May 2018, the FDA approved Lucemyra (lofexidine hydrochloride), the first non-opioid medication aimed at easing withdrawal symptoms in adults discontinuing opioid use. Lucemyra works by reducing norepinephrine release, a neurotransmitter linked to withdrawal symptoms. While it can lessen symptom severity, it does not completely prevent them and is approved for treatment durations of up to 14 days.

• Leading companies advancing OWS therapies include Chiesi Farmaceutici S.p.A., BioXcel Therapeutics, Aphios Pharmaceutical, and others.

• Notable pipeline candidates in development include CHF-6563, BXCL501, among others.

Opioid Withdrawal Syndrome Pipeline Analysis

The Opioid Withdrawal Syndrome pipeline insights report 2025, provides insights into:

• Provides comprehensive insights into key companies developing therapies in the Opioid Withdrawal Syndrome Market.

• Categorizes Opioid Withdrawal Syndrome therapeutic companies by development stage: early, mid, and late-stage.

• Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

• Reviews emerging Opioid Withdrawal Syndrome drugs under development based on:

  • Stage of development

  • Opioid Withdrawal Syndrome Route of administration

  • Target receptor

  • Monotherapy vs. combination therapy

  • Opioid Withdrawal Syndrome Mechanism of action

  • Molecular type

• Offers detailed analysis of:

  • Company-to-company and company-academia collaborations

  • Opioid Withdrawal Syndrome Licensing agreements

  • Funding and investment activities supporting future Opioid Withdrawal Syndrome market advancement.

Request for a sample report @

Opioid Withdrawal Syndrome Emerging Drugs

• CHF-6563: Chiesi Farmaceutici S.p.A.

• BXCL501: BioXcel Therapeutics

Opioid Withdrawal Syndrome Companies

More than four leading companies are actively developing treatments for Opioid Withdrawal Syndrome, with Chiesi Farmaceutici S.p.A. advancing a drug candidate to the most advanced stage to date-Phase II clinical trials.

DelveInsight's report covers around 4+ products under different phases of Opioid Withdrawal Syndrome clinical trials like

• Opioid Withdrawal Syndrome Late stage Therapies (Phase III)

• Opioid Withdrawal Syndrome Mid-stage Therapies (Phase II)

• Opioid Withdrawal Syndrome Early-stage Therapies (Phase I)

• Opioid Withdrawal Syndrome Pre-clinical and Opioid Withdrawal Syndrome Discovery stage Therapies

• Opioid Withdrawal Syndrome Discontinued & Inactive Therapies

Opioid Withdrawal Syndrome pipeline report provides the Opioid Withdrawal Syndrome therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Opioid Withdrawal Syndrome Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Opioid Withdrawal Syndrome Therapies and Key Opioid Withdrawal Syndrome Companies: Opioid Withdrawal Syndrome Clinical Trials and recent advancements

Opioid Withdrawal Syndrome Pipeline Therapeutic Assessment

. Opioid Withdrawal Syndrome Assessment by Product Type

. Opioid Withdrawal Syndrome By Stage

. Opioid Withdrawal Syndrome Assessment by Route of Administration

. Opioid Withdrawal Syndrome Assessment by Molecule Type

Download Opioid Withdrawal Syndrome Sample report to know in detail about the Opioid Withdrawal Syndrome treatment market @ Opioid Withdrawal Syndrome Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Opioid Withdrawal Syndrome Current Treatment Patterns

4. Opioid Withdrawal Syndrome - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Opioid Withdrawal Syndrome Late-Stage Products (Phase-III)

7. Opioid Withdrawal Syndrome Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Opioid Withdrawal Syndrome Discontinued Products

13. Opioid Withdrawal Syndrome Product Profiles

14. Opioid Withdrawal Syndrome Key Companies

15. Opioid Withdrawal Syndrome Key Products

16. Dormant and Discontinued Products

17. Opioid Withdrawal Syndrome Unmet Needs

18. Opioid Withdrawal Syndrome Future Perspectives

19. Opioid Withdrawal Syndrome Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Opioid Withdrawal Syndrome Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

MENAFN01092025003238003268ID1110002611